IL4I1, ITGB7, and FUT7, which were identified by comprehensive bioinformatic analysis, may play a vital role in the tumour immune microenvironment and hold the potential of enhancing ICB treatment by remodelling glucose metabolism. The gene discussed is IL4I1; the disease is neoplasm.